AU2017305508B2 - N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors - Google Patents

N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors Download PDF

Info

Publication number
AU2017305508B2
AU2017305508B2 AU2017305508A AU2017305508A AU2017305508B2 AU 2017305508 B2 AU2017305508 B2 AU 2017305508B2 AU 2017305508 A AU2017305508 A AU 2017305508A AU 2017305508 A AU2017305508 A AU 2017305508A AU 2017305508 B2 AU2017305508 B2 AU 2017305508B2
Authority
AU
Australia
Prior art keywords
methyl
compound
cancer
disclosure
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017305508A
Other languages
English (en)
Other versions
AU2017305508A1 (en
Inventor
Jianyong Chen
Shaomeng Wang
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan System
Original Assignee
University of Michigan System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Michigan System filed Critical University of Michigan System
Publication of AU2017305508A1 publication Critical patent/AU2017305508A1/en
Application granted granted Critical
Publication of AU2017305508B2 publication Critical patent/AU2017305508B2/en
Priority to AU2021202113A priority Critical patent/AU2021202113B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Hydrogenated Pyridines (AREA)
AU2017305508A 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors Active AU2017305508B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2021202113A AU2021202113B2 (en) 2016-08-05 2021-04-06 N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 Inhibitors

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662371504P 2016-08-05 2016-08-05
US62/371,504 2016-08-05
US201762454101P 2017-02-03 2017-02-03
US62/454,101 2017-02-03
PCT/US2017/045428 WO2018027097A1 (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2021202113A Division AU2021202113B2 (en) 2016-08-05 2021-04-06 N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 Inhibitors

Publications (2)

Publication Number Publication Date
AU2017305508A1 AU2017305508A1 (en) 2019-02-07
AU2017305508B2 true AU2017305508B2 (en) 2021-01-07

Family

ID=59677319

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2017305508A Active AU2017305508B2 (en) 2016-08-05 2017-08-04 N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 inhibitors
AU2021202113A Active AU2021202113B2 (en) 2016-08-05 2021-04-06 N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 Inhibitors

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2021202113A Active AU2021202113B2 (en) 2016-08-05 2021-04-06 N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 Inhibitors

Country Status (27)

Country Link
US (3) US10829488B2 (OSRAM)
EP (3) EP3494115B1 (OSRAM)
JP (2) JP6651180B2 (OSRAM)
KR (2) KR102429704B1 (OSRAM)
CN (2) CN110483501B (OSRAM)
AU (2) AU2017305508B2 (OSRAM)
CA (1) CA3031419C (OSRAM)
CY (1) CY1123859T1 (OSRAM)
DK (1) DK3494115T3 (OSRAM)
ES (1) ES2849959T3 (OSRAM)
HR (1) HRP20202073T1 (OSRAM)
HU (1) HUE053414T2 (OSRAM)
IL (2) IL264059B (OSRAM)
LT (1) LT3494115T (OSRAM)
MX (2) MX381588B (OSRAM)
MY (1) MY199409A (OSRAM)
PE (1) PE20190711A1 (OSRAM)
PH (1) PH12019500231A1 (OSRAM)
PT (1) PT3494115T (OSRAM)
RS (1) RS61821B1 (OSRAM)
RU (2) RU2722560C1 (OSRAM)
SA (1) SA519401020B1 (OSRAM)
SG (2) SG10201913643YA (OSRAM)
SI (1) SI3494115T1 (OSRAM)
SM (1) SMT202100025T1 (OSRAM)
WO (1) WO2018027097A1 (OSRAM)
ZA (2) ZA201900240B (OSRAM)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11001582B2 (en) * 2016-03-10 2021-05-11 Assia Chemical Industries Ltd. Solid state forms of Venetoclax and processes for preparation of Venetoclax
LT3494115T (lt) * 2016-08-05 2021-01-25 The Regents Of The University Of Michigan N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai
WO2018127130A1 (en) 2017-01-07 2018-07-12 Shanghai Fochon Pharmaceutical Co., Ltd. Compounds as bcl-2-selective apoptosis-inducing agents
PT3612531T (pt) * 2017-04-18 2022-10-04 Shanghai Fochon Pharmaceutical Co Ltd Agentes indutores de apoptose
US11420968B2 (en) 2018-04-29 2022-08-23 Beigene, Ltd. Bcl-2 inhibitors
TWI752335B (zh) * 2018-07-31 2022-01-11 大陸商蘇州亞盛藥業有限公司 Bcl-2抑制劑與MDM2抑制劑的組合產品及其在預防及/或治療疾病中的用途
UA125241C2 (uk) * 2018-07-31 2022-02-02 Есентейдж Фарма (Сучжоу) Ко., Лтд. СИНЕРГІЧНИЙ ПРОТИПУХЛИННИЙ ЕФЕКТ ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З РИТУКСИМАБОМ ТА/АБО БЕНДАМУСТИНОМ АБО ІНГІБІТОРА Bcl-2 В ПОЄДНАННІ З CHOP
CN110772521A (zh) 2018-07-31 2020-02-11 苏州亚盛药业有限公司 Bcl-2抑制剂或Bcl-2/Bcl-xL抑制剂与BTK抑制剂的组合产品及其用途
AU2019314819A1 (en) * 2018-07-31 2020-10-22 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of Bcl-2 inhibitor and chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
CN111214471B (zh) * 2018-11-23 2021-04-02 苏州亚盛药业有限公司 药物组合物及其用途
TWI770503B (zh) * 2019-05-13 2022-07-11 大陸商蘇州亞盛藥業有限公司 用於預測bcl-2/bcl-xl抑制劑對癌症的功效的方法和組合物
TW202114692A (zh) * 2019-07-02 2021-04-16 大陸商蘇州亞盛藥業有限公司 一種含有mTOR抑制劑的藥物組合及其應用
AU2020321068A1 (en) * 2019-07-31 2021-03-18 Ascentage Pharma (Suzhou) Co., Ltd. Combination product of a Bcl-2/Bcl-xL inhibitor and a chemotherapeutic agent and use thereof in the prevention and/or treatment of diseases
WO2021104442A1 (en) * 2019-11-27 2021-06-03 Ascentage Pharma (Suzhou) Co., Ltd. Method and compositions for predicting anti-cancer efficacy of compounds targeting apoptosis pathway
TWI772992B (zh) * 2019-12-03 2022-08-01 大陸商蘇州亞盛藥業有限公司 作為bcl-2抑制劑的n-(苯基磺醯基)苯甲醯胺及相關化合物
CN118542872A (zh) * 2019-12-04 2024-08-27 苏州亚盛药业有限公司 药物组合及其用途
JP7142173B2 (ja) 2019-12-06 2022-09-26 ロクソ オンコロジー， インコーポレイテッド ブルトン型チロシンキナーゼ阻害剤の投薬
WO2021175321A1 (en) 2020-03-06 2021-09-10 Ascentage Pharma (Suzhou) Co., Ltd. Crystalline forms or amorphous forms of n- (phenyl sulfonyl) benzamide compounds or its salts or solvates
US20230128137A1 (en) * 2020-03-12 2023-04-27 Medshine Discovery Inc. Benzo five-membered cyclic compound
IL296582A (en) 2020-04-15 2022-11-01 Beigene Ltd bcl-2 inhibitor
WO2021227763A1 (en) * 2020-05-14 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Hplc analysis method for n- (phenylsulfonyl) benzamide compound
WO2022002178A1 (en) * 2020-07-01 2022-01-06 Ascentage Pharma (Suzhou) Co., Ltd. Methods for synthesizing n-(phenylsulfonyl)benzamide compounds and intermediates thereof
CN111537654B (zh) * 2020-07-07 2020-11-10 上海亚盛医药科技有限公司 N-(苯基磺酰基)苯甲酰胺化合物的hplc分析方法
KR20230038231A (ko) * 2020-07-10 2023-03-17 지앙수 헨그루이 파마슈티컬스 컴퍼니 리미티드 술포닐벤즈아미드 유도체 및 이의 접합체, 이의 제조 방법 및 이의 용도
CN114057728A (zh) * 2020-08-06 2022-02-18 北京诺诚健华医药科技有限公司 作为bcl-2抑制剂的杂环化合物
US20230398110A1 (en) * 2020-08-21 2023-12-14 Ascentage Pharma (Suzhou) Co., Ltd. Compositions and methods for treating non-alcoholic steatohepatitis
CN114073707A (zh) * 2020-08-21 2022-02-22 苏州亚盛药业有限公司 治疗系统性红斑狼疮的组合物和方法
WO2022111558A1 (en) * 2020-11-25 2022-06-02 Ascentage Pharma (Suzhou) Co., Ltd. Solid dispersion, pharmaceutical preparations, preparation method, and application thereof
CN114681458B (zh) * 2020-12-28 2023-07-18 苏州亚盛药业有限公司 治疗多发性硬化症的方法
CN114835704B (zh) * 2021-02-01 2023-10-27 苏州亚盛药业有限公司 作为bcl-2抑制剂的磺酰基苯甲酰胺衍生物
US20250319183A1 (en) 2021-04-07 2025-10-16 David Avigan Compositions and methods for the treatment of cancer
JP2024528174A (ja) 2021-08-02 2024-07-26 アセンテージ ファーマ（スーチョウ）カンパニー，リミティド 医薬組合せおよびその使用
KR20240135747A (ko) * 2021-12-06 2024-09-12 항저우 힐젠 테라퓨틱스 컴퍼니 리미티드 항-세포사멸 단백질 bcl-2 억제제, 약학적 조성물 및 이의 응용
CN115260191B (zh) * 2022-09-29 2022-12-27 上海睿跃生物科技有限公司 哌啶类化合物及其制备方法和应用
EP4421075A1 (en) * 2023-02-27 2024-08-28 KRKA, d.d., Novo mesto Process for the preparation of venetoclax and intermediates used therein
WO2024184233A1 (en) 2023-03-03 2024-09-12 Ionctura Sa Combination of roginolisib and bcl-2 inhibitor in the treatment of haematological malignancy

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305122A1 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2012058392A1 (en) * 2010-10-29 2012-05-03 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
WO2012071374A1 (en) * 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1021343A (en) 1912-01-17 1912-03-26 M A N Mfg Company Locking-clamp.
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
WO2005049593A2 (en) 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
US7767684B2 (en) * 2003-11-13 2010-08-03 Abbott Laboratories Apoptosis promoters
US8624027B2 (en) 2005-05-12 2014-01-07 Abbvie Inc. Combination therapy for treating cancer and diagnostic assays for use therein
WO2008030836A2 (en) 2006-09-05 2008-03-13 Abbott Laboratories Bcl inhibitors treating platelet excess
AU2007329458A1 (en) 2006-12-04 2008-06-12 Abbott Laboratories Companion diagnostic assays for cancer therapy
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
CA2744711C (en) 2008-12-05 2017-06-27 Abbott Laboratories Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
AU2010204555B2 (en) 2009-01-19 2013-03-07 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
JP2012517241A (ja) 2009-02-11 2012-08-02 アボット・ラボラトリーズ Ｂｃｌ−２ファミリー阻害剤耐性腫瘍及び癌を有する被験者を同定、分類及びモニターするための方法及び組成物
PE20120345A1 (es) 2009-05-26 2012-05-17 Abbvie Bahamas Ltd Derivados de 2-(1h-pirrolo[2,3-b]piridin-5-iloxi)-n-fenilsulfonilbenzamida como inhibidores de proteinas anti-apoptoticas
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
SG190361A1 (en) 2010-11-23 2013-06-28 Abbvie Inc Salts and crystalline forms of an apoptosis-inducing agent
JP6960912B2 (ja) 2015-12-30 2021-11-05 デックスコム・インコーポレーテッド 感度プロファイルに基づく留置センサの工場校正または不完全校正のためのシステム及び方法
LT3494115T (lt) 2016-08-05 2021-01-25 The Regents Of The University Of Michigan N-(fenilsulfonil)benzamido dariniai kaip bcl-2 inhibitoriai

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100305122A1 (en) * 2009-05-26 2010-12-02 Abbott Laboratories Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2012058392A1 (en) * 2010-10-29 2012-05-03 Abbott Laboratories Solid dispersions containing an apoptosis-inducing agent
WO2012071374A1 (en) * 2010-11-23 2012-05-31 Abbott Laboratories Methods of treatment using selective bcl-2 inhibitors

Also Published As

Publication number Publication date
US20180354950A1 (en) 2018-12-13
AU2021202113B2 (en) 2022-08-18
RU2020114660A3 (OSRAM) 2020-09-15
SG11201900135YA (en) 2019-02-27
PT3494115T (pt) 2021-01-15
IL264059A (en) 2019-01-31
MX381588B (es) 2025-03-12
CN110483501A (zh) 2019-11-22
MY199409A (en) 2023-10-25
SG10201913643YA (en) 2020-03-30
RU2020134802A (ru) 2022-04-25
KR20190035710A (ko) 2019-04-03
US20190315739A1 (en) 2019-10-17
CY1123859T1 (el) 2022-05-27
ES2849959T3 (es) 2021-08-24
RU2020114660A (ru) 2020-06-19
IL282099B (en) 2022-03-01
NZ750100A (en) 2021-01-29
EP3569601A2 (en) 2019-11-20
KR20210107170A (ko) 2021-08-31
EP4129999A1 (en) 2023-02-08
CN109311871A (zh) 2019-02-05
EP3569601B1 (en) 2022-06-22
LT3494115T (lt) 2021-01-25
IL264059B (en) 2021-05-31
EP3494115A1 (en) 2019-06-12
IL282099A (en) 2021-05-31
EP3494115B1 (en) 2020-10-21
SA519401020B1 (ar) 2022-03-16
HRP20202073T1 (hr) 2021-02-19
US10221174B2 (en) 2019-03-05
RS61821B1 (sr) 2021-06-30
AU2021202113A1 (en) 2021-05-06
CA3031419C (en) 2021-08-24
JP2020007311A (ja) 2020-01-16
CA3031419A1 (en) 2018-02-08
CN110483501B (zh) 2022-07-01
US20210002277A1 (en) 2021-01-07
US11718613B2 (en) 2023-08-08
EP3569601A3 (en) 2019-11-27
CN109311871B (zh) 2020-02-28
DK3494115T3 (da) 2021-01-18
BR112019001666A2 (pt) 2019-05-28
PH12019500231A1 (en) 2019-07-29
ZA201900240B (en) 2020-05-27
RU2722560C1 (ru) 2020-06-01
HUE053414T2 (hu) 2021-06-28
MX2019001391A (es) 2019-06-06
US10829488B2 (en) 2020-11-10
SMT202100025T1 (it) 2021-03-15
WO2018027097A1 (en) 2018-02-08
JP6651180B2 (ja) 2020-02-19
PE20190711A1 (es) 2019-05-17
ZA201908466B (en) 2020-05-27
JP2019527705A (ja) 2019-10-03
MX2020013014A (es) 2021-02-22
SI3494115T1 (sl) 2021-02-26
KR102429704B1 (ko) 2022-08-04
JP7205903B2 (ja) 2023-01-17
RU2744358C2 (ru) 2021-03-05
AU2017305508A1 (en) 2019-02-07
KR102376764B1 (ko) 2022-03-18

Similar Documents

Publication Publication Date Title
AU2021202113B2 (en) N-(phenylsulfonyl)benzamides and related compounds as Bcl-2 Inhibitors
AU2018269947B2 (en) Pyrrolo(2,3-c)pyridines and related analogs as LSD-1 inhibitors
RU2831159C2 (ru) N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
RU2831159C9 (ru) N-(фенилсульфонил) бензамиды и родственные соединения в качестве ингибиторов bcl-2
US20240166644A1 (en) Sulfonyl benzamide derivatives as bcl-2 inhibitors
HK40019323A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40019323B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40001725A (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
HK40001725B (en) N-(phenylsulfonyl)benzamide derivatives as bcl-2 inhibitors
NZ750100B2 (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
BR112019001666B1 (pt) Compostos de n-(fenilsulfonil)benzamidas e sais e solvatos dos mesmos, composições farmacêuticas e seus usos no tratamento de doenças, distúrbios ou afecções através da inibição de bcl-2
HK40001439B (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors
HK40001439A (en) N-(phenylsulfonyl)benzamides and related compounds as bcl-2 inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)